Pre-Clinical Studies of ExoPTEN
The study indicates that ExoPTEN therapy enables new connections to be made, effectively repairing the transected spinal cord, at least partially.
For humans, this study suggests that ExoTherapy may facilitate even a partial recovery, providing patients with a better outcome than had been possible to date.
Intranasal ExoPTEN promotes Axon growth functional recovery
- Weekly BBB locomotor scores of SCI rats left untreated (Transection), or treated with Intranasal Exosome (Exosome IN), or intranasal Exosome with PTEN-siRNA (ExoPTEN IN).
- BBB score: Ranges from 0 to 21. 0 means total paralysis while 21 means perfect walking
Representative electrophysiological traces in healthy (black), ExoPTEN-treated (green, and re-transection below in cyanine), and exosome-treated rats (purple, retransection below in pink)
The outcome of the research, as set out in the patent application, can be summarized as follows:
a) Pharmaceutical composition comprising EVs loaded with a PTEN inhibitor.
b) Pharmaceutical composition comprising EVs loaded with an exogenous PTEN inhibitor, for use in treating a neurological disease, disorder or condition.
c) Method of treating a neurological disease, disorder or condition, comprising administering to the subject a therapeutically effective amount of membrane particles loaded with a PTEN inhibitor, thereby treating the neurological disease or condition. The membrane particles may be ESV derived from cells.
d) Isolated EVs loaded with a PTEN inhibitor.
e) The EVs selected from the group consisting of exosomes, microvesicles, membrane particles, membrane vesicles, ectosomes and exovesicles.
f) EVs are a combination of exosomes and microvesicles. Exosomes derived from adherent cells expressing mesenchymal markers.
g) The adherent cells expressing mesenchymal markers are selected from mesenchymal stem cells, oral mucosa stem cells or olfactory ensheathing cells.
h) EVs such as exosomes, are derived from adherent cells expressing markers from neural crest cells.